The Effect of Thymoquinone Administration on Local Immunoglobulin-G Levels of Rattus norvegicus Strain Wistar Sciatic Nerve Crush Injury Model

Valentinus Besin, Abdul Hafid Bajamal, Mohammad Hasan Machfoed, Jusak Nugraha, Budi Utomo, Paulus Budiono Notopuro


BACKGROUND: Immunoglobulin-G (IgG) is a product of the initial response to secondary immune response, which accumulates in distal segment of the nerve after crush injury. Thymoquinone modulates the adaptive immune response. Effect of thymoquinone administration on local IgG levels of Rattus norvegicus Wistar rats sciatic nerve crush injury model has not been elucidated.

METHODS: This was an experimental study, with 63 Rattus norvegicus Wistar rats that divided into 9 groups. Three groups were given placebo, 3 groups were given 100 mg/kg/day thymoquinone, and 3 groups were given 250 mg/kg/day thymoquinone. The rats were terminated based on the assigned group at 5x24, 6x24, and 7x24 hours and then the IgG levels were measured using sandwich enzyme-linked immunosorbent assay (ELISA).

RESULTS: There was a significant difference in IgG levels after administration of 100 and 250 mg/kg/day thymoquinone at 5x24 hours and 7x24 hours post-injury compared to the rats that were given no treatment. A significant difference of IgG levels was also found after administration of 100 mg/kg/day thymoquinone group at 6x24 hours post-injury. Critical point of decreasing local IgG of all groups happened at 6x24 hours after injury, however, there was no significant difference in the median levels of thymoquinone at doses of 100 mg/kg and 250 mg/kg.

CONCLUSION: Local IgG levels in distal segment of the sciatic nerve crush injury is lower in rats that were given 100 mg/kg thymoquinone treatment compared to the rats that receive no thymoquinone treatment since 5x24 hours after injury. Thymoquione administration should be given immediately after the crush injury until before 6x24 hours post-injury to decrease antibodies in degeneration process.

KEYWORDS: thymoquinone, immunoglobulin-G, crush injury, sciatic nerve

Full Text:



Menorca RM, Fussell TS, Elfar JC. Nerve physiology: mechanisms of injury and recovery. Hand Clin. 2013; 29(3): 317-30, CrossRef.

Immerman I, Price AE, Alfonso I, Grossman JA. Lower extremity nerve trauma. Bull Hosp Jt Dis. 2014; 72(1): 43-52, PMID.

Issack PS, Helfet DL. Sciatic nerve injury associated with acetabular fractures. HSS J. 2009; 5(1): 12-8, CrossRef.

Alvites R, Caseiro AR, Pedrosa SS, Branquinho MV, Ronchi G, Geuna S, et al. Peripheral nerve injury and axonotmesis: state of the art and recent advances. Cogent Med. 2018; 5(1): 1466404, CrossRef.

Mietto BS, Mostacada K, Martinez AM. Neurotrauma and inflammation: CNS and PNS responses. Mediators Inflamm. 2015; 2015: 251204, CrossRef.

Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci. 2007; 30: 153-79, CrossRef.

Chen YM, Shen RW, Zhang B, Zhang WN. Regional tissue immune responses after sciatic nerve injury in rats. Int J Clin Exp Med. 2015; 8(8): 13408-12, PMID.

Yuan W, Feng X. Immune cell distribution and immunoglobulin levels change following sciatic nerve injury in a rat model. Iran J Basic Med Sci. 2016; 19(7): 794-9, PMID.

Majdalawieh AF, Fayyad MW. Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: a comprehensive review. Int Immunopharmacol. 2015; 28(1): 295-304, CrossRef.

Javanbakht J, Hobbenaghi R, Hosseini E, Bahrami AM, Khadivar F, Fathi S, Hassan MA. Histopathological investigation of neuroprotective effects of Nigella sativa on motor neurons anterior horn spinal cord after sciatic nerve crush in rats. Pathol Biol (Paris). 2013; 61(6): 250-3, CrossRef.

Kanter M. Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy. Neurochem Res. 2008; 33(1): 87-96, CrossRef.

Sereflican M, Yurttas V, Ozyalvacli G, Terzi EH, Turkoglu SA, Yildiz S, et al. The histopathological and electrophysiological effects of thymoquinone and methylprednisolone in a rabbit traumatic facial nerve paralysis model. Am J Otolaryngol. 2016; 37(5): 407-15, CrossRef.

Farkhondeh T, Samarghandian S, Shahri AMP, Samini F. The neuroprotective effects of thymoquinone: a review. Dose Response. 2018; 16(2): 1559325818761455, CrossRef.

Bauder AR, Ferguson TA. Reproducible mouse sciatic nerve crush and subsequent assessment of regeneration by whole mount muscle analysis. J Vis Exp. 2012; 2012(60): 3606, CrossRef.

Gladman SJ, Huang W, Lim SN, Dyall SC, Kang JX, Knight MM, et al. Improved outcome after peripheral nerve injury in rats with increased levels of endogenous ω-3 polyunsaturated fatty acids. J Neurosci. 2012; 32(2): 563-71, CrossRef.

Ogden M, Karaca SB, Aydin G, Yuksel U, Dagli AT, Akkaya S, Bakar B. The healing effects of thymoquinone and dexpanthenol in sciatic nerve compression injury in rats. J Invest Surg. 2021; 34(5): 504-12, CrossRef.

Elabscicne. Rat IgG (Immunoglobulin G) ELISA Kit Catalog No : E-EL-R0518. 6th Edition. Elabscience: Wuhan; 2021, article.

El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC. Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol. 2006; 6(7): 1135-42, CrossRef.

Xu H, Timares L, Elmets CA. 19 – Host defenses in skin. In: Rich RR, Fleisher TA, Weyand M, editors. Clinical Imunology: Principles and Practice. 5th Edition. Amsterdam: Elsevier; 2019. p.273-83, NLMID.

Meiliana A, Wijaya A. Macrophage polarization in metabolism and metabolic disease. Indones Biomed J. 2013; 5(2): 81-90, CrossRef.

Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine. 2015; 74(2): 318-26, CrossRef.

Heine G, Drozdenko G, Grün JR, Chang HD, Radbruch A, Worm M. Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur J Immunol. 2014; 44(6): 1615-21, CrossRef.

Celik F, Göçmez C, Karaman H, Kamaşak K, Kaplan I, Akıl E, Tufek A, Guzel A, Uzar E. Therapeutic effects of thymoquinone in a model of neuropathic pain. Curr Ther Res Clin Exp. 2014; 76: 11-6, CrossRef.

Lacagnina MJ, Heijnen CJ, Watkins LR, Grace PM. Autoimmune regulation of chronic pain. Pain Rep. 2021; 6(1): e905, CrossRef.

Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017; 8: 603, CrossRef.


Copyright (c) 2022 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute